Published in Women's Health Weekly, April 14th, 2005
According to recent research published in the journal Breast Cancer Research and Treatment, "vascular endothelial growth factor (VEGF-A) is considered a prognostic indicator for clinical outcome in breast cancer. Conflicting results nevertheless exist and there is a need for larger studies including untreated patients in order to clarify the importance of tumor-specific VEGF-A regarding prognosis as well as potential links to predictive treatment information."
"VEGF-A and its receptor, vascular endothelial growth receptor 2 (VEGFR-2), were therefore analyzed by...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly